A new pharmacological strategy -- based on engineering protein surfaces -- just achieved major success against pancreatic cancer.
It points toward a much broader class of cancer therapies.
Yesterday, the FDA approved daraxonrasib (Rasonque), a drug that targets the RAS proteins driving most pancreatic cancers. What makes it especially fascinating is how it works.
Rather than simply finding a conventional pocket on RAS, daraxonrasib binds the chaperone protein cyclophilin A and uses it to create a new protein surface. This drug–cyclophilin complex then engages active RAS, forming a three-part complex that blocks RAS interactions with downstream effectors. Remarkably, the complex can also stimulate GTP hydrolysis, further suppressing RAS signaling.
This is chemical biology at its most powerful: a small molecule is not merely inhibiting a protein: It is engineering a new protein–protein interaction inside the cell to pharmacologically control a previously “undruggable” protein.
The clinical impact is already impressive: in a randomized phase III trial, median survival in metastatic pancreatic cancer increased from 6.7 to 13.2 months compared with standard chemotherapy.
🔷 Perhaps the most exciting aspect is what comes next. If we can pharmacologically engineer new protein surfaces and interactions, rather than being restricted to naturally occurring binding pockets, the universe of druggable proteins—and potentially the range of cancers we can treat—could expand dramatically.
A beautiful example of how understanding and engineering proteins can open entirely new therapeutic possibilities.
This is a great read from @Waymo on lessons learned for autonomy.
I'll admit I was over optimistic about end-to-end neutral networks and in vision only systems but neither has seemed to pan out.
The "humans can drive with just visual sensors" argument always misses that our "cameras" are on a 6DOF pivot (our head) and that we can deploy glare protection (sunshade, sunglasses) in realtime.
https://t.co/WJ7A40VNfK
This is orders of magnitude harder than the Covid vaccine, with Covid you are creating a foreign antigen, with cancer , you have to get the body to attack self with high specificity, really amazing stuff
Moderna and @Merck today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene, a novel investigational mRNA-based individualized neoantigen therapy jointly developed by Merck and Moderna, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with completely resected Stage IIB-IV melanoma.
Read more:
Hi Tobi, thanks for the feedback! We are working on making Claude Code more hackable, which will include being able to easily use Agents.MD or make other system prompt modifications. I’ll share more here when it’s ready to roll out.
Our reasoning for this was that we don't think that model families are interchangeable and the system prompt can have a big impact on performance.
I wrote here: https://t.co/WCXcDYJlwq on how Claude models like their skills, system prompt, Claude.MD, etc to be formatted. In Claude Code we have different system prompts per model.
That said, I know this is a lot of upkeep and not worth the squeeze for everyone. Feedback heard and I'll keep you posted.
In the immediate term, you can always @Agents.MD from your Claude.MD.
@rwaliany Not sure if you’re aware, but your company is running a Craigslist scam where they show properties that aren’t available at a low price for the purpose of contact farming, it’s probably an accident but looks unethical without all the context
@StreetsblogUSA@cyrusphall @Streetsblog Yeah but they do that by making cars worse, muni is faster, more frequent and more comprehensive than SBB trams
@docmilanfar https://t.co/1Kzmr1bvTO
Sam is an amazing marketer and the MSFT deal was very smart IMO, but now that G is taking on more product risk, it’s going to be hard for OpenAI to keep the best people - first mover advantage rarely beats better distribution channels
@Austen You have to charge within 48 hours of arrest and you can’t re-charge if you don’t win, DA must’ve had an issue with getting the witnesses so is just taking more time, resist the group think Austen, think from first principles :)
@improbapaul Im starting to see it win in anything that is conversational and has a decision tree, some talk therapy, light friendship, some medical triaging
@pt Would you be against them suing Marlboro for marketing to kids? It’s kind of hard to differentiate between addictive algorithms and addictive substances, maybe the same societal rules should apply to both?
Swyft Cities is here to revolutionize transportation and real estate! An innovative gondola system combines autonomous pods w/ lightweight, fixed cable infrastructure to move passengers efficiently w/ significantly lower cost-per-mile & less emissions than traditional options.👇